Đorđevic, Aleksandar

Link to this page

Authority KeyName Variants
a130d507-c029-4e18-8180-e1f09f9dd326
  • Đorđevic, Aleksandar (1)
Projects

Author's Bibliography

Hepatoprotective effect of fullerenol/doxorubicin nanocomposite in acute treatment of healthy rats

Petrović, Daniela; Seke, Mariana; Labudović Borović, Milica; Jović, Danica; Borišev, Ivana; Srđenovic, Branislava; Rakočević, Zlatko; Pavlović, Vladimir B.; Đorđevic, Aleksandar

(Elsevier, 2018)

TY  - JOUR
AU  - Petrović, Daniela
AU  - Seke, Mariana
AU  - Labudović Borović, Milica
AU  - Jović, Danica
AU  - Borišev, Ivana
AU  - Srđenovic, Branislava
AU  - Rakočević, Zlatko
AU  - Pavlović, Vladimir B.
AU  - Đorđevic, Aleksandar
PY  - 2018
UR  - https://dais.sanu.ac.rs/123456789/3755
AB  - In our recent studies we have designed fullerenol/doxorubicin nanocomposite (FNP/DOX) as the new drug nanocarrier. This research has demonstrated that this novel nanocomposite has had better implications on the liver tissue in vivo (Wistar rats treated intraperitoneally), than treatment based only on DOX. FNP/DOX has been characterised by DLS, TEM and AFM measurements which have shown that DOX loaded onto FNP did not influence fullerenol nanoparticle's size. FNP/DOX affected oxidative status in blood causing a significant decrease of catalase and SOD activity in comparison to DOX, implicating the reduction in oxidative stress. qRT-PCR results on the mRNA level of antioxidative enzymes (catalase and MnSOD) revealed that the effect of oxidative stress is significantly reduced by the treatment with FNP/DOX (p <.05). The ultrastructural analysis of the liver tissue has revealed that FNP/DOX nanocomposite generated considerably less damage in the liver tissue, than DOX applied at the same dose. Hence, our results have indicated that FNP, within FNP/DOX nanocomposite, exhibits protective effects to the liver tissue of the healthy rats. © 2018
PB  - Elsevier
T2  - Experimental and Molecular Pathology
T1  - Hepatoprotective effect of fullerenol/doxorubicin nanocomposite in acute treatment of healthy rats
SP  - 199
EP  - 211
VL  - 104
IS  - 3
DO  - 10.1016/j.yexmp.2018.04.005
UR  - https://hdl.handle.net/21.15107/rcub_dais_3755
ER  - 
@article{
author = "Petrović, Daniela and Seke, Mariana and Labudović Borović, Milica and Jović, Danica and Borišev, Ivana and Srđenovic, Branislava and Rakočević, Zlatko and Pavlović, Vladimir B. and Đorđevic, Aleksandar",
year = "2018",
abstract = "In our recent studies we have designed fullerenol/doxorubicin nanocomposite (FNP/DOX) as the new drug nanocarrier. This research has demonstrated that this novel nanocomposite has had better implications on the liver tissue in vivo (Wistar rats treated intraperitoneally), than treatment based only on DOX. FNP/DOX has been characterised by DLS, TEM and AFM measurements which have shown that DOX loaded onto FNP did not influence fullerenol nanoparticle's size. FNP/DOX affected oxidative status in blood causing a significant decrease of catalase and SOD activity in comparison to DOX, implicating the reduction in oxidative stress. qRT-PCR results on the mRNA level of antioxidative enzymes (catalase and MnSOD) revealed that the effect of oxidative stress is significantly reduced by the treatment with FNP/DOX (p <.05). The ultrastructural analysis of the liver tissue has revealed that FNP/DOX nanocomposite generated considerably less damage in the liver tissue, than DOX applied at the same dose. Hence, our results have indicated that FNP, within FNP/DOX nanocomposite, exhibits protective effects to the liver tissue of the healthy rats. © 2018",
publisher = "Elsevier",
journal = "Experimental and Molecular Pathology",
title = "Hepatoprotective effect of fullerenol/doxorubicin nanocomposite in acute treatment of healthy rats",
pages = "199-211",
volume = "104",
number = "3",
doi = "10.1016/j.yexmp.2018.04.005",
url = "https://hdl.handle.net/21.15107/rcub_dais_3755"
}
Petrović, D., Seke, M., Labudović Borović, M., Jović, D., Borišev, I., Srđenovic, B., Rakočević, Z., Pavlović, V. B.,& Đorđevic, A.. (2018). Hepatoprotective effect of fullerenol/doxorubicin nanocomposite in acute treatment of healthy rats. in Experimental and Molecular Pathology
Elsevier., 104(3), 199-211.
https://doi.org/10.1016/j.yexmp.2018.04.005
https://hdl.handle.net/21.15107/rcub_dais_3755
Petrović D, Seke M, Labudović Borović M, Jović D, Borišev I, Srđenovic B, Rakočević Z, Pavlović VB, Đorđevic A. Hepatoprotective effect of fullerenol/doxorubicin nanocomposite in acute treatment of healthy rats. in Experimental and Molecular Pathology. 2018;104(3):199-211.
doi:10.1016/j.yexmp.2018.04.005
https://hdl.handle.net/21.15107/rcub_dais_3755 .
Petrović, Daniela, Seke, Mariana, Labudović Borović, Milica, Jović, Danica, Borišev, Ivana, Srđenovic, Branislava, Rakočević, Zlatko, Pavlović, Vladimir B., Đorđevic, Aleksandar, "Hepatoprotective effect of fullerenol/doxorubicin nanocomposite in acute treatment of healthy rats" in Experimental and Molecular Pathology, 104, no. 3 (2018):199-211,
https://doi.org/10.1016/j.yexmp.2018.04.005 .,
https://hdl.handle.net/21.15107/rcub_dais_3755 .
16
10
16